Cancer is a sneaky disease. Find one method of treating it successfully, and it finds another way to survive. Take, for example, pediatric diffuse midline gliomas, brain tumors that are among the most ...

Diffuse gliomas, which account for the majority of malignant brain tumors in adults, comprise astrocytoma, oligodendroglioma, and glioblastoma. Current diagnosis of glioma types requires combining ...

Modeyso is the first FDA-approved systemic therapy for H3 K27M-mutant diffuse midline glioma, targeting both adult and pediatric patients. Clinical trials demonstrated a 22% overall response rate with ...

Dordaviprone targets mitochondrial protease and dopamine receptor D2, representing a novel approach in cancer therapy for H3 K27M-mutant diffuse glioma. The drug application seeks accelerated FDA ...

Diffuse gliomas are malignant brain tumors and cannot be optimally examined by conventional imaging using MRI. Amino acid PET can better visualize the activity and spread of gliomas. An international ...

Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet for this rare cancer. But researchers now have a ...

Please provide your email address to receive an email when new articles are posted on . A patient’s frailty should be considered when determining fractionation for WHO grade 4 adult-type diffuse ...

What Is Modeyso, and Why Does It Matter? Modeyso (dordaviprone) is a new oral medicine that treats a rare and aggressive brain tumor, called diffuse midline glioma (DMG), that has a tumor mutation ...

Diffuse intrinsic pontine glioma (DIPG) is an almost universally fatal brain pediatric tumor and the only tumor indication where palliative radiotherapy is the current standard of care. Although ...